

OZANIMOD capsules (Zeposia® ▼) for ulcerative colitis

The Pan Mersey Area Prescribing Committee recommends the prescribing of OZANIMOD capsules (Zeposia® ▼), by specialists only, for ulcerative colitis, in accordance with NICE TA828.

RED

[NICE technology appraisal \(TA\) 828](#) (05 October 2022) recommends ozanimod as an option for treating moderately to severely active ulcerative colitis in adults, only if:

- > conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable,
or
- > biological treatment cannot be tolerated or is not working well enough,
and
- > the company provides it according to the commercial arrangement^[1]

Prescribing and monitoring of therapy must be retained by a specialist in the management of ulcerative colitis.

Costing information

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population). This is because ozanimod is a further treatment option and the overall cost of treatment will be similar to the current treatment options.^[2]

References

1. National Institute for Health and Care Excellence. Technology Appraisal 828; [Ozanimod for treating moderately to severely active ulcerative colitis](#), 05 October 2022. Accessed online 10 October 2022.
2. National Institute for Health and Care Excellence. Technology Appraisal 828; [Resource impact statement: Ozanimod for treating moderately to severely active ulcerative colitis](#), 05 October 2022. Accessed online 14 October 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.